Hepatitis B Outcomes After Switching to Long-Acting Cabotegravir/Rilpivirine in People With HIV: Reactivation, Incident Infection, and Liver Safety Across Diverse Serological Profiles
Clinical Infectious Diseases · 08.07.2026 · 82 (6) · 1015-1022
DOI: 10.1093/cid/ciag023 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Infectious Diseases, online erschienen am 14.01.2026. Verfasst von Alberto Foncillas und 16 weiteren Autor:innen. Beteiligte Einrichtung: HIV Unit, Infectious Diseases Service, Hospital Clínic Barcelona-Instituto de Investigaciones Biomédicas August Pi i Sunyer (IDIBAPS), Barcelona, Spa…. Hauptthemen laut MEDLINE: Hepatitis B, HIV Infections, Anti-HIV Agents, Pyridones. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 47 Literaturangaben.
Abstract (Originalsprache)
Background
Long-acting cabotegravir/rilpivirine (LA-CAB/RPV) therapy for HIV, lacks activity against hepatitis B virus (HBV). We evaluate HBV serological profiles and risk of HBV reactivation (HBVr) or incident infection (HBVi) in people with HIV (PWH) switching to LA-CAB/RPV.
Methods
Prospective cohort study of PWH initiating LA-CAB/RPV at Hospital Clínic Barcelona between February/2023 and February/2025. HBV serology, vaccination status, and liver function tests (LFTs) were assessed at baseline. Follow-up LFTs were performed routinely (weeks 12, 28, and every 6 months), and HBV serology/DNA assessed if abnormal LFTs, acute hepatitis or clinical suspicion of reactivation. HBVr was defined as conversion from HBsAg negative to positive or detectable HBV DNA in anti-HBc-positive/HBsAg-negative individuals, or as HBV DNA ≥1 log increase or ≥100 IU/mL in chronic HBV (HBsAg-positive) participants. HBVi was defined as HBsAg seroconversion in HBV unexposed individuals.
Results
Among 741 participants-92% cis-gender male, median age 43 (IQR 35–52)-454 (61%) had vaccine-induced immunity and 25% had prior HBV exposure (anti-HBc-positive), with 3% showing isolated anti-HBc. Median follow-up was 54 weeks (IQR 28–77). No HBVr or HBVi were observed in people without chronic hepatitis at baseline. Four individuals (0.5%) with unnoticed chronic HBV infection (HBsAg-positive) started LA-CAB/RPV; two developed clinical HBVr and two remained stable after regimen switch, all four switched back to tenofovir-containing therapy. Transaminase elevations during follow-up occurred in 17% of the cohort, regardless of HBV serostatus.
Conclusions
LA-CAB/RPV appears safe in individuals with prior HBV exposure, including isolated anti-HBc. Comprehensive HBV screening, vaccination, and liver monitoring are essential.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- HIV Unit, Infectious Diseases Service, Hospital Clínic Barcelona-Instituto de Investigaciones Biomédicas August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
- Faculty of Medicine, University of Barcelona, Barcelona, Spain.
- Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.
- Reial Academia de Medicina de Catalunya (RAMC), Barcelona, Spain.
ORCID-Profile: Alberto Foncillas, Julia Calvo, Iván Chivite, María Martínez-Rebollar, José M Miró, Elisa de Lazzari, Esteban Martínez, Josep Mallolas, Ana González-Cordón, Montserrat Laguno
Zitieren
APA
Foncillas, A., Ambrosioni, J., Sempere, A., Berrocal, L., Calvo, J., Chivite, I., de la Mora, L., Inciarte, A., Torres, B., Martínez-Rebollar, M., Blanco, J. L., Miró, J. M., de Lazzari, E., Martínez, E., Mallolas, J., González-Cordón, A., & Laguno, M. (2026). Hepatitis B Outcomes After Switching to Long-Acting Cabotegravir/Rilpivirine in People With HIV: Reactivation, Incident Infection, and Liver Safety Across Diverse Serological Profiles. Clinical Infectious Diseases, 82(6), 1015-1022. https://doi.org/10.1093/cid/ciag023
Vancouver
Foncillas A, Ambrosioni J, Sempere A, Berrocal L, Calvo J, Chivite I, et al. Hepatitis B Outcomes After Switching to Long-Acting Cabotegravir/Rilpivirine in People With HIV: Reactivation, Incident Infection, and Liver Safety Across Diverse Serological Profiles. Clinical Infectious Diseases. 2026;82(6):1015-1022. doi:10.1093/cid/ciag023
BibTeX
@article{Foncillas2026,
author = {Foncillas, Alberto and Ambrosioni, Juan and Sempere, Abiu and Berrocal, Leire and Calvo, Julia and Chivite, Iván and de la Mora, Lorena and Inciarte, Alexy and Torres, Berta and Martínez-Rebollar, María and Blanco, José Luis and Miró, José M and de Lazzari, Elisa and Martínez, Esteban and Mallolas, Josep and González-Cordón, Ana and Laguno, Montserrat},
title = {Hepatitis B Outcomes After Switching to Long-Acting Cabotegravir/Rilpivirine in People With HIV: Reactivation, Incident Infection, and Liver Safety Across Diverse Serological Profiles},
journal = {Clinical Infectious Diseases},
year = {2026},
volume = {82},
number = {6},
pages = {1015--1022},
doi = {10.1093/cid/ciag023}
}
EUVIMED